Infinitopes Precision Immunomics

Infinitopes Precision Immunomics

Private
OxfordHealthcare & Life Scienceshttps://infinitopes.com

Last Round

Seed

Jan 21, 2026

Total Funding Raised

$35.1M

Company Overview

Infinitopes Precision Immunomics is a clinical-stage biotechnology company that develops cancer vaccines using its precision antigen discovery platform and proprietary vector delivery systems.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine

Business Model

B2G

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

cancer vaccinesoff-the-shelf vaccineimmuno-oncologyAI drug discoveryantigen discoveryT-cell therapytherapeutic vaccinescancer immunotherapyprecision medicinecancer biotechvector delivery systemclinical-stage biotechcancer recurrencemetastasis preventionoesophageal cancerinnovative licensing and access pathwayILAP

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Infinitopes Precision Immunomics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Infinitopes Precision Immunomics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
SeedJan 21, 2026

Key People

Founding team and executive leadership

Marcus Harrison

Interim Chief Operating Officer

Executive Team

Infinitopes Precision Immunomics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 21, 2026

    $35.1M raised in Seed funding.

  • Mar 20, 2025

    Jo Brewer appointed as Non-Executive Director

Infinitopes Precision Immunomics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Infinitopes Precision Immunomics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Infinitopes Precision Immunomics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range28
Year Founded2021
Last FundingJan 21, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.